Author

Alexandra Livanova

Human TechnopoleORCID 0000-0002-4694-6411Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:benchmarking· 1 Assay:ChIP-seq· 1 Research Focus:database / resource· 1

Frequent Co-Authors

Andrea SottorivaiD· 2 shared Luca AzzoliniD· 2 shared A. SarachakoviD· 1 shared Abir Kumar PandaiD· 1 shared Alessandra RaimondiiD· 1 shared Alex Rossi· 1 shared Alexander BagaeviD· 1 shared Amber Leila SarvestaniiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Andrea SottorivaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BioinformaticsbioRxivPreprintSep 12, 2026

CRISPR-enhanced assessment of variants of unknown significance nominates oncology therapeutic targets and drug repositioning opportunities

Aurora Savino, Athanasios Oikonomou, Francesca Perrone…·Francesco Iorio

CRISPR-VUS identifies rare variants linked to gene dependency in cancer cell lines, prioritizing potential drivers and therapeutic targets through functional validation.

DOI 10.64898/2026.01.20.700565

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 11, 2026

Epigenetic evolution of colorectal cancer and its microenvironment reveals new vulnerabilities

Alexandra Livanova, Luca Azzolin, Francesco Cambuli…·Andrea Sottoriva

This study examines the epigenetic evolution of colorectal cancer and its microenvironment, identifying new therapeutic targets through single-cell analysis and functional validation.

DOI 10.64898/2026.08.10.743840

humanChIP-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 26, 2025

A simple circuit to sustain intact tumor microenvironments for complex drug interrogations

Amber Leila Sarvestani, Samantha M. Ruff, Kirsten Remmert…·Jonathan Matthew Hernandez

The paper develops a perfusion circuit system to preserve tumor microenvironments in 3D patient-derived tumor models for up to 48 hours, enabling complex drug interrogations.

DOI 10.1101/2025.10.26.684624

humanbulk RNA-seq

𝕏 PostBluesky